Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2022-04-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于2022年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding the expected related party transactions for the year 2022. It includes details about the nature of the transactions, pricing principles, amounts, independent directors' opinions, supervisory board opinions, and sponsor opinions. The document is a formal disclosure about anticipated related party transactions, which is a regulatory announcement rather than a full financial report or detailed management discussion. It does not contain comprehensive financial statements or detailed financial analysis. The document length is about 5569 characters, which is relatively short and consistent with an announcement. It is not an annual report, interim report, earnings release, or any other detailed financial report. It is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS).
2022-04-26 Chinese
关于2021年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding the 2021 annual profit distribution plan. It includes details about the company's net profit, the decision not to distribute cash dividends or bonus shares, and the plan to submit this proposal to the 2021 annual shareholders' meeting for approval. The document contains no full financial statements or comprehensive financial performance data but rather focuses on the profit distribution proposal and related board and independent director opinions. The document length is short (1275 characters), and it is an announcement of a profit distribution plan rather than a full annual report or interim report. This fits the category of Notice of Dividend Amount (DIV), as it announces the dividend distribution plan (in this case, no dividend).
2022-04-26 Chinese
独立董事事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement of prior approval opinions from independent directors regarding two matters: the company's 2022 related party transactions and the reappointment of the 2022 audit firm. It references regulatory guidelines and company bylaws, and is signed by independent directors. The document is short (975 characters) and does not contain financial statements or detailed audit reports. It is a governance-related document expressing independent directors' opinions before board approval, not the audit report itself or the annual report. Therefore, it fits best under Board/Management Information (MANG), as it relates to board-level approvals and governance matters.
2022-04-26 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report' for Tian Kang Biological Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021. The content includes detailed descriptions of internal control standards, evaluation scope, procedures, and conclusions about the absence of significant internal control deficiencies. The document is a standalone report focused on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it relates to internal control and audit matters rather than a full annual report or other filing types. The document length is 3624 characters, which is relatively short but contains substantive evaluation content, not merely an announcement or certification. Therefore, it fits best under the Audit Report / Information (AR) category. FY 2021
2022-04-26 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding changes in accounting policies. It details the reasons for the changes, the specific accounting policies affected, the impact on financial statements, and the approvals from the board, independent directors, and supervisory board. The document does not contain full financial statements or comprehensive financial performance data but rather focuses on the policy change announcement and its implications. The length is 2626 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a regulatory certification or officer attestation. Therefore, the document fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories but involve important company disclosures such as accounting policy changes.
2022-04-26 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled "天康生物股份有限公司 2021 年年度报告全文" which translates to "Tian Kang Biology Co., Ltd. 2021 Annual Report Full Text." It contains detailed financial data for the fiscal year 2021, including revenue, profit, cash flow, segment analysis, and management discussion and analysis. The document includes comprehensive sections such as company overview, financial indicators, management discussion, governance, environmental and social responsibility, and detailed financial statements. The length is substantial (15,000 characters), and the content is consistent with a full annual report rather than a brief announcement or a supplementary document. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-26 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.